Literature DB >> 23257919

Substance P decreases fat storage and increases adipocytokine production in 3T3-L1 adipocytes.

Pierre Miegueu1, David H St-Pierre, Marc Lapointe, Pegah Poursharifi, HuiLing Lu, Abhishek Gupta, Katherine Cianflone.   

Abstract

Obesity, inflammation, and insulin resistance are closely linked. Substance P (SP), via its neurokinin 1 receptor (NK1R), mediates inflammatory and, possibly, neuroendocrine processes. We examined SP effects on lipid storage and cytokine production in 3T3-L1 adipocytes and adipose tissues. 3T3-L1 adipocytes and preadipocytes express NK1R, and 8 days of SP supplementation during differentiation to 3T3-L1 preadipocytes decreased lipid droplet accumulation. SP (10 nM, 24 h) increased lipolysis in primary adipocytes (138 ± 7%, P < 0.05) and reduced fatty acid uptake (-31 ± 7%, P < 0.05) and mRNA expression of the differentiation-related transcription factors peroxisome proliferator-activated receptor-γ type 2 (-64 ± 2%, P < 0.001) and CCAAT enhancer-binding protein (CEBP)-α (-65 ± 2%, P < 0.001) and the lipid storage genes fatty acid-binding protein type 4 (-59 ± 2%, P < 0.001) and diacylglycerol O-acyltransferase-1 (-45 ± 2%, P < 0.01) in 3T3-L1 adipocytes, while CD36, a fatty acid transporter (+82 ± 19%, P < 0.01), was augmented. SP increased secretion of complement C3 (148 ± 15%, P < 0.04), monocyte chemoattractant protein-1 (156 ± 16%, P < 0.03), and keratinocyte-derived chemokine (148 ± 18%, P = 0.045) in 3T3-L1 adipocytes and monocyte chemoattractant protein-1 (496 ± 142%, P < 0.02) and complement C3 (152 ± 25%, P < 0.04) in adipose tissue and primary adipocytes, respectively. These SP effects were accompanied by downregulation of insulin receptor substrate 1 (-82 ± 2%, P < 0.01) and GLUT4 (-76 ± 2%, P < 0.01) mRNA expression, and SP acutely blocked insulin-mediated stimulation of fatty acid uptake and Akt phosphorylation. Although adiponectin secretion was unchanged, mRNA expression was decreased (-86 ± 8%, P < 0.001). In humans, NK1R expression correlates positively with plasma insulin, fatty acid, and complement C3 and negatively with adiponectin, CEBPα, CEBPβ, and peroxisome proliferator-activated receptor-γ mRNA expression in omental, but not subcutaneous, adipose tissue. Our results suggest that, beyond its neuroendocrine and inflammatory effects, SP could also be involved in targeting adipose tissue and influencing insulin resistance.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23257919     DOI: 10.1152/ajpgi.00162.2012

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  6 in total

1.  EVALUATION OF PLASMA SUBSTANCE P AND BETA-ENDORPHIN LEVELS IN CHILDREN WITH PRADER-WILLI SYNDROME.

Authors:  M G Butler; T A Nelson; D J Driscoll; A M Manzardo
Journal:  J Rare Disord       Date:  2015-09

Review 2.  Evolution of the Marrow Adipose Tissue Microenvironment.

Authors:  Clarissa S Craft; Erica L Scheller
Journal:  Calcif Tissue Int       Date:  2016-07-01       Impact factor: 4.333

Review 3.  Neural regulation of bone marrow adipose tissue.

Authors:  Xiao Zhang; Mohamed G Hassan; Erica L Scheller
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2021-03-15       Impact factor: 5.667

4.  Replacement of Lost Substance P Reduces Fibrosis in the Diabetic Heart by Preventing Adverse Fibroblast and Macrophage Phenotype Changes.

Authors:  Alexander Widiapradja; Ainsley O Kasparian; Samuel L McCaffrey; Lauren L Kolb; John D Imig; Jessica L Lacey; Giselle C Melendez; Scott P Levick
Journal:  Cells       Date:  2021-10-05       Impact factor: 6.600

5.  Substance P enhances the activation of AMPK and cellular lipid accumulation in 3T3‑L1 cells in response to high levels of glucose.

Authors:  Maria Jose Dubon; Yeji Byeon; Ki-Sook Park
Journal:  Mol Med Rep       Date:  2015-10-16       Impact factor: 2.952

6.  The NK1R-/- mouse phenotype suggests that small body size, with a sex- and diet-dependent excess in body mass and fat, are physical biomarkers for a human endophenotype with vulnerability to attention deficit hyperactivity disorder.

Authors:  Katharine Pillidge; David J Heal; S Clare Stanford
Journal:  J Psychopharmacol       Date:  2016-07-26       Impact factor: 4.153

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.